Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522380

Total Parenteral Nutrition in Clinical Practice: The Pharmacist's Role in Prescribing Support, Preparation, and Risk Management

Bejad Muteb Saad Alotaibi [(1)] , Ali Hasan Ali Gharawi [(2)] , Adel Ali Alshehri [(3)] , Abdulrahman Saleh Alanazi [(4)] , Abdullah Shaya Hamad Aldossari [(5)] , Ali Ibrahim Abdullah Faqeeri [(6)] , Fayez Fayadh Helal Alanazi [(7)] , Mohammed Ali Mohammed Alsahli [(8)] , Mohammed Muqbil Alqahtani [(8)] , Rahma Turki Hassan Alshamrani [(9)] , Saud Nasser Salem Alotaibi [(8)] , Hussain Habib Al Abdullah [(10)]

(1) Irada and Mental Health Hospital in Al Kharj,Ministry of Health, Saudi Arabia,
(2) Sabya General Hospital, Jizan Branch,Ministry of Health, Saudi Arabia,
(3) King Salman Hospital , Ministry of Health, Saudi Arabia,
(4) Al Muzahmiyah General Hospital,Ministry of Health, Saudi Arabia,
(5) Dental Clinic, South Riyadh,Ministry of Health, Saudi Arabia,
(6) Al Faqrah Primary Health Care, Western Sector, Jazan,Ministry of Health, Saudi Arabia,
(7) King Khalid Hospital In Al Kharj, Ministry of Health, Saudi Arabia,
(8) Rawidat Al-Ared General Hospital, Ministry of Health, Saudi Arabia,
(9) Al-Thaghr General Hospital,Ministry of Health, Saudi Arabia,
(10) King Fahad Specialist Hospital – Dammam,Ministry of Health, Saudi Arabia

Abstract

Background: Total parenteral nutrition (TPN) is a critical intervention for patients unable to meet nutritional needs via the gastrointestinal tract. It delivers macronutrients and micronutrients intravenously, bypassing digestion and absorption, but carries significant risks requiring multidisciplinary oversight.

Aim: To review the pharmacist's role in prescribing support, preparation, and risk management of TPN, emphasizing clinical indications, mechanisms, administration, adverse effects, contraindications, monitoring, and toxicity.

Methods: A comprehensive literature review was conducted, synthesizing evidence-based guidelines and clinical studies on TPN formulation, administration strategies, and safety considerations.

Results: TPN is indicated in conditions such as bowel obstruction, high-output fistulas, severe malabsorption, and prolonged NPO status. Its mechanism involves intravenous delivery of carbohydrates, amino acids, lipids, electrolytes, vitamins, and trace elements, tailored to patient-specific needs. Administration requires central venous access and strict aseptic technique. Adverse effects include catheter-related complications, infections, metabolic disturbances (e.g., refeeding syndrome, dysglycemia), and hepatobiliary dysfunction. Contraindications include functional GI tract, irreversible neurological injury, and critical instability. Monitoring protocols emphasize frequent assessment of electrolytes, renal function, and glucose. Toxicity risks arise from overfeeding, trace element accumulation, and oxidative damage. Pharmacists play a pivotal role in compounding stability, compatibility checks, and interdisciplinary coordination.

Conclusion: TPN is a high-risk, lifesaving therapy requiring individualized prescriptions, vigilant monitoring, and collaborative care to optimize outcomes and minimize complications.

Keywords: Total parenteral nutrition, intravenous nutrition, pharmacist role, metabolic complications, risk management, monitoring, toxicity

Introduction

Parenteral nutrition refers to the delivery of macronutrients and micronutrients directly into the systemic circulation through intravenous (IV) administration, thereby bypassing the gastrointestinal (GI) tract. This therapeutic approach is reserved for clinical situations in which the digestive system is unable to absorb or tolerate adequate nutrition, or when using the GI tract would be unsafe. Within the broader category of parenteral nutrition, total parenteral nutrition (TPN) denotes a complete nutritional regimen delivered intravenously as the sole source of caloric intake and essential nutrients. In other words, patients receiving TPN are not obtaining meaningful nutrition through oral intake or tube feeding, and therefore the IV formulation must provide comprehensive support, including energy substrate, amino acids, essential fatty acids, electrolytes, vitamins, trace elements, and fluid as clinically appropriate. Because TPN is inherently invasive and associated with risks related to venous access and metabolic complications, its use is

*Corresponding author e-mail: bejadma@moh.gov.sa (Bejad Muteb Saad Alotaibi).
Receive Date: 29 November 2025, Revise Date: 24 December 2025, Accept Date: 26 December 2025

generally justified when there is impaired GI function accompanied by contraindications to enteral nutrition or an inability to meet nutritional goals via the enteral route. In most clinical contexts, enteral nutrition is preferred when feasible, reflecting both physiological and practical advantages. Nutrition delivered through the GI tract helps preserve gut mucosal integrity, supports normal enterohepatic and immunologic function, and is typically simpler and less costly to administer. Enteral feeding is also associated with a lower incidence of certain complications, notably catheter-related bloodstream infections and thrombosis, which are more directly linked to central venous access devices commonly required for TPN. However, these benefits are contingent upon having a functional GI system capable of digestion and absorption; therefore, when the GI tract is nonfunctional, obstructed, severely inflamed, or otherwise unable to tolerate feeding, parenteral nutrition becomes an essential alternative.[1] TPN, in particular, is indicated when parenteral nutrition must serve as the exclusive nutritional strategy, typically because enteral feeding is either contraindicated or inadequate to sustain nutritional status.

Several clinical indications for TPN have been described in the literature, reflecting conditions that either prevent adequate transit and absorption of nutrients or require intentional limitation of luminal stimulation. As outlined by Chowdary and Reddy (2010), TPN is appropriately considered across a range of scenarios in which nutritional requirements cannot be met through enteral means.[2] One such indication is chronic intestinal obstruction, including obstruction associated with intestinal malignancy, where mechanical blockage prevents effective progression of enteral feeds and places patients at risk of aspiration, severe discomfort, and worsening obstruction if feeding is attempted.[3] Similarly, bowel pseudo-obstruction accompanied by food intolerance may necessitate TPN when motility is functionally impaired to the extent that enteral nutrition cannot be advanced safely or effectively. In these contexts, the goal of TPN is not merely caloric replacement but prevention of progressive malnutrition while the underlying pathology is treated or stabilized. TPN may also be employed as part of a bowel rest strategy in selected GI fistulas, particularly those characterized by high output. High-flow fistulas can lead to profound fluid and electrolyte losses, impaired nutrient absorption, and exacerbation of output when enteral feeding increases luminal flow. In such cases, TPN can help reduce enteric stimulation, support tissue repair, and maintain nutritional status while definitive management proceeds.[4] Another important population includes neonates and infants in whom the GI tract is either developmentally immature or affected by congenital malformations that disrupt normal feeding and absorption. In these patients, TPN can serve as a bridge to growth and stabilization until enteral feeding becomes feasible or surgical correction is completed. Postoperative complications represent further situations in which TPN may be clinically indicated. A postoperative bowel anastomosis leak, for example, often necessitates restriction of enteral intake to limit luminal flow across the compromised site and to reduce the risk of further contamination, while ensuring that patients receive adequate nutrition during a period of increased metabolic demand. Likewise, patients who experience persistent inability to maintain nutritional status due to severe diarrhea or vomiting may require TPN when oral intake is not tolerated and enteral feeding cannot be maintained or fails to meet requirements. Such patients are at risk of rapid depletion of protein stores, electrolyte abnormalities, and worsening clinical outcomes if nutritional support is delayed.



Fig. 1: TPN administration lines.

Small bowel obstruction constitutes another indication in which enteral nutrition may be contraindicated or impractical, depending on the severity and location of the obstruction and the feasibility of postpyloric feeding beyond the obstructed segment. When obstruction prevents adequate delivery or absorption of nutrients, TPN becomes a supportive measure that can sustain nutritional needs while definitive medical or surgical management is undertaken. In addition, hypercatabolic states—such as those associated with sepsis, polytrauma, or major fractures—can rapidly increase nutritional requirements and accelerate protein breakdown. In these situations, when enteral nutrition is not achievable or fails to provide sufficient intake, TPN may be used to meet metabolic needs and mitigate the adverse effects of severe catabolism.[5] A common clinical scenario prompting consideration of TPN is an anticipated prolonged period of nothing-by-mouth (NPO) status. When patients are expected to be unable to receive enteral intake for more than seven days, as may occur during

severe exacerbations of inflammatory bowel disease or in critically ill individuals requiring prolonged ventilatory support and complex hemodynamic management, parenteral nutrition may be indicated to prevent progressive malnutrition and to support recovery.[6] The decision to initiate TPN in such cases is often individualized and depends on baseline nutritional status, severity of illness, and projected duration of inadequate enteral intake, but the guiding principle remains the same: when the GI tract cannot be used effectively for a clinically meaningful duration, comprehensive IV nutritional support may be required. In the United States, the use of parenteral nutrition products occurs within a regulatory framework overseen by the Food and Drug Administration (FDA). The FDA regulates parenteral nutrition and requires statistically significant evidence of both efficacy and safety for parenteral nutrition products, reflecting the high-stakes nature of sterile injectable formulations and their potential for serious adverse events. As a result, there are postapproval clinical trial requirements for parenteral nutrition products, intended to ensure ongoing evaluation of real-world performance and to strengthen the evidence base that informs safe clinical use.[7] This regulatory oversight underscores that TPN is not simply an "alternative feeding method," but a complex pharmacotherapy-like intervention requiring standardized formulation practices, careful monitoring, and continual alignment with evolving safety data.

Mechanism of Action

Total parenteral nutrition (TPN) functions as a comprehensive, intravenous method of providing macronutrients and micronutrients to patients who cannot safely or effectively use the gastrointestinal tract for nutrition. From a mechanistic standpoint, TPN replaces the physiologic processes of digestion, absorption, and nutrient assimilation that normally occur through enteral intake by delivering substrates directly into the bloodstream, where they can be distributed to tissues and metabolized according to cellular demand. The "mechanism" of TPN is therefore not a single pharmacologic action but a coordinated metabolic support strategy. It supplies energy, nitrogen, essential fatty acids, electrolytes, vitamins, minerals, and trace elements in proportions designed to maintain or restore anabolic balance, preserve lean body mass, support immune and wound-healing functions, and prevent nutrient deficiencies. Because patient requirements vary substantially with illness severity, organ function, age, and catabolic state, clinicians are expected to individualize TPN composition to meet the specific physiologic needs of each patient.[8][9] This individualized formulation is fundamental to the clinical efficacy of TPN and differentiates it from standardized fluid replacement, as TPN serves as a complete metabolic substrate system rather than a simple volume-expanding infusion. TPN is composed of separate components that are combined to create a nutritionally complete admixture, typically including lipid emulsions, dextrose, amino acids, vitamins, electrolytes, minerals, and trace elements.[8][9] Each component contributes a distinct physiologic role, and together they provide the substrates needed for cellular respiration, protein synthesis, membrane integrity, enzymatic activity, and maintenance of osmotic and acid–base homeostasis. The three principal macronutrients—lipid emulsions, protein (amino acid solutions), and carbohydrate (dextrose)—form the caloric backbone of TPN. Their relative contributions are adjusted to balance energy delivery with metabolic tolerance, to avoid complications such as hyperglycemia or hypertriglyceridemia, and to ensure that caloric provision does not outpace the patient's capacity for oxidative metabolism. In addition to macronutrients, micronutrients are incorporated to prevent deficiency states and to sustain biochemical pathways that depend on vitamins and trace elements as cofactors.



Fig. 2: TPN.

Lipid emulsions provide a dense source of calories and play a crucial role in preventing essential fatty acid deficiency, a clinically significant complication that can develop within approximately three weeks when TPN is administered without fat.[2] Physiologically, lipids supply essential fatty acids required for membrane phospholipid synthesis, eicosanoid production, and maintenance of skin and hair integrity, among other functions. Their provision also enables a reduction in reliance on dextrose, thereby limiting excessive carbohydrate loads that could contribute to hyperglycemia, hepatic steatosis, or excess carbon dioxide production. In most adult regimens, approximately 25% to 30% of total calories are delivered as lipids, a distribution that supports both energy needs and essential fatty acid sufficiency while offering flexibility in caloric design.[2] The metabolic "action" of lipids in TPN is therefore twofold: they directly contribute to energy production

through oxidation and they supply indispensable structural and regulatory fatty acids that cannot be synthesized de novo in sufficient quantities. Protein provision in TPN is achieved through amino acid solutions that contain a combination of essential and nonessential amino acids, although some mixtures remain incomplete with respect to certain amino acids under particular physiological conditions.[2] Amino acids serve as the nitrogen source required for protein synthesis, tissue repair, immune mediators, and enzymatic proteins, and they are essential for preventing negative nitrogen balance, particularly in catabolic states. In healthy adults, the protein requirement is commonly estimated at approximately 0.8 to 1 g/kg/day, but clinical conditions substantially modify this need.[2] Critically ill patients often require higher protein delivery, such as 1.5 g/kg/day, reflecting increased proteolysis, inflammatory stress responses, and heightened requirements for wound healing and immune function. Conversely, patients with chronic renal failure may receive lower protein targets such as 0.6 to 0.8 g/kg/day to reduce nitrogenous waste burden when clearance is impaired, although requirements must be reassessed in the context of dialysis. For example, patients receiving hemodialysis may require 1.2 to 1.3 g/kg/day because dialysis can increase amino acid losses and because adequate protein is necessary to maintain muscle mass and support recovery.[2] Hepatic encephalopathy introduces another context where temporary protein restriction to around 0.8 g/kg/day may be applied, largely as a short-term strategy to minimize ammonia-related neurotoxicity while stabilizing hepatic function.[2] Mechanistically, amino acid delivery supports anabolism and nitrogen equilibrium, but if misaligned with organ function and metabolic capacity, it can also contribute to complications such as azotemia or worsening encephalopathy, which underscores why protein dosing in TPN is always an individualized prescription rather than a fixed formula.

Carbohydrate provision is delivered primarily through dextrose monohydrate, available in multiple concentrations, commonly 40%, 50%, and 70% solutions, which are then compounded to achieve the desired final dextrose load.[8] Dextrose functions as a readily oxidizable energy substrate and supports glucose-dependent tissues and pathways, including central nervous system function, glycolytic energy production, and the generation of intermediates for biosynthetic processes. However, the metabolic capacity to utilize glucose is finite and can be impaired in stress states characterized by insulin resistance, such as critical illness, sepsis, or corticosteroid exposure. A commonly cited maximal rate of glucose utilization is approximately 5 to 7 mg/kg/min, beyond which the risk of metabolic derangements increases.[2] Excessive carbohydrate administration can precipitate hyperglycemia, which may increase infection risk and osmotic diuresis, and it may also contribute to hypertriglyceridemia through de novo lipogenesis, particularly when insulin-mediated pathways are overwhelmed. Therefore, the "action" of dextrose within TPN is to supply energy efficiently while requiring careful titration and monitoring to avoid metabolic toxicity. Micronutrients—electrolytes, trace elements, and vitamins—are integral to TPN's mechanism because they maintain physiologic homeostasis and support biochemical reactions essential for life. Trace elements and vitamin doses are often aligned with recommended daily requirements, although clinical conditions such as renal dysfunction, cholestasis, burns, or high-output losses can necessitate adjustment.[8][9] Electrolyte provision in TPN commonly follows general per-liter targets, with sodium typically ranging from 100 to 150 mEq, potassium from 50 to 100 mEq, magnesium from 8 to 24 mEq, calcium from 10 to 20 mEq, and phosphorus from 15 to 30 mEq per liter.[2] These values represent broad guidance rather than rigid standards, as the patient's serum levels, acid–base status, ongoing losses, renal function, and concurrent medications must be considered. Mechanistically, these electrolytes regulate membrane potentials, neuromuscular function, intracellular signaling, and ATP-dependent processes. Phosphate is particularly important for energy metabolism, oxygen delivery (through 2,3-BPG in red blood cells), and cell membrane integrity, while magnesium and potassium are essential for cardiac stability and enzymatic function. Vitamins and trace elements act as coenzymes and cofactors in numerous metabolic pathways, including oxidative phosphorylation and antioxidant defense, and their omission can lead to rapid deficiency syndromes in patients reliant on TPN as their sole nutrient source.

Modern practice frequently delivers total nutrition as a combined admixture, often described as total nutrient admixture (TNA) or a "3-in-1" formulation, in which dextrose, amino acids, and lipid emulsion are mixed together with electrolytes, trace elements, vitamins, and water.[8] This approach contrasts with earlier "2-in-1" strategies, in which dextrose and amino acids were combined while lipid emulsions were infused separately.[8] The preference for a 3-in-1 strategy in adult practice is grounded in workflow efficiency and the ability to provide continuous, balanced substrate delivery through a single infusion line, though institutional protocols and patient factors may influence whether a 2-in-1 regimen is selected. Regardless of the configuration, the essential mechanistic goal is the same: to provide complete nutrition intravenously, sustaining metabolic needs when the GI tract cannot be used. A notable limitation in TPN formulation relates to amino acid completeness. The amino acid mixtures commonly used in TPN continue to be described as

incomplete, containing only 19 amino acids in standard formulations.[10] This has motivated interest in supplementing specific amino acids under certain conditions, particularly glutamine, which is often categorized as "conditionally essential" during severe stress. Glutamine has been used as a complement to TPN to help complete amino acid content, with glutamine content in parenteral nutrition sometimes cited in the range of approximately 8% to 10% as a complement.[10] The rationale for glutamine supplementation arises from observations that critically ill surgical patients may exhibit reduced glutamine levels upon admission, with further declines over subsequent intensive care days, suggesting depletion during catabolic stress. In a study referenced by Tsuji, both high (greater than or equal to 700 nmol/mL) and low (less than 400 nmol/mL) glutamine levels in ICU patients were statistically associated with increased mortality compared to intermediate levels between 400 and 700 nmol/mL.[11] These findings complicate simplistic assumptions that "more glutamine is better," supporting the more nuanced position that glutamine should be used as a complement rather than as pharmaco-nutrition delivered at supranutritional doses.

Safety considerations further refine glutamine use. As referenced by Heyland et al., certain critically ill populations should not receive glutamine complementation beyond what might be present in basal TPN formulations, including patients with septic shock, those with hemodynamic instability requiring escalating vasopressor support, and patients with renal failure.[12] Mechanistically, this caution reflects the reality that amino acid metabolism and clearance can be profoundly altered in shock states and renal dysfunction, potentially creating metabolic burdens or unintended physiologic consequences when supplementation is aggressive. The broader implication is that TPN "mechanism" is inseparable from clinical pharmacology principles: nutrient substrates function beneficially within physiologic ranges and appropriate contexts, but may become harmful when delivered without regard to altered organ function or stress physiology. From a pharmaceutical standpoint, the mechanism of TPN also includes the requirement that the compounded mixture remains physicochemically and microbiologically stable throughout preparation, storage, and administration. TPN is not only a nutritional intervention but also a complex sterile compounded product, and its clinical success depends on maintaining emulsion stability, preventing precipitation, and minimizing contamination risk.[13] The interaction among components—particularly calcium and phosphate salts, trace elements, pH, and lipid emulsion integrity—can lead to clinically hazardous events if incompatibilities occur. Therefore, TPN preparation requires careful analysis of composition and potential interactions that may manifest during compounding, refrigeration, warming to room temperature, and infusion through central or peripheral venous access.[13] These stability requirements are integral to the therapy's effective "delivery mechanism," because a nutritionally appropriate prescription can become unsafe if the compounded admixture is unstable or contaminated.

Compatibility considerations extend to the real-world context in which hospitalized patients receiving TPN also require multiple IV medications. Y-site administration—where medications and TPN share a common IV line via a Y-connector—can introduce risks of physical incompatibility, precipitation, or emulsion disruption. In one study evaluating physical compatibility of various drugs with neonatal TPN during Y-site coadministration, amiodarone, phenobarbital, and rifampin produced visible precipitation and therefore should not be administered via Y-site injection with neonatal TPN solutions.[14] Such precipitation is not merely an aesthetic concern; crystal formation can occlude catheters, compromise nutrient delivery, and potentially lead to embolic events if particulate matter enters the bloodstream. Consequently, clinicians are advised to consult compatibility references for individual drugs when coadministering with parenteral nutrition, thereby avoiding preventable hazards associated with incompatibility and crystal formation.[15] This aspect underscores a key pharmaceutical dimension of TPN's mechanism: the therapy is delivered through IV systems that often simultaneously deliver medications, and safe coadministration requires systematic compatibility verification. In summary, TPN operates through a comprehensive metabolic support mechanism that supplies energy substrates and essential nutrients intravenously to sustain physiologic function when enteral feeding is not possible. Lipid emulsions deliver dense calories and prevent essential fatty acid deficiency, amino acid solutions provide nitrogen for anabolism and tissue repair with dosing tailored to clinical condition, and dextrose supplies carbohydrate energy within metabolic utilization limits to avoid hyperglycemia and hyperlipidemia.[2][8][9] Micronutrients maintain electrolyte balance and biochemical pathway integrity, and TPN is commonly delivered as an integrated 3-in-1 admixture that has become standard in adult care.[8] The evolving understanding of amino acid completeness and glutamine supplementation emphasizes that nutrient dosing must remain physiologically grounded and context-specific, with special caution in septic shock, hemodynamic instability, and renal failure.[10][11][12] Finally, the pharmaceutical requirements for stability and compatibility—including attention to Y-site interactions—are central to the safe and effective implementation of TPN as a complex sterile compounded therapy.[13][14][15]

Administration

The administration of total parenteral nutrition (TPN) is a highly regulated clinical process that combines principles of vascular access management, sterile infusion practice, metabolic monitoring, and individualized nutrition therapy. Because TPN solutions deliver concentrated macronutrients and electrolytes directly into the circulation and often have high osmolarity, safe administration requires reliable central venous access and rigorous protocols designed to prevent catheter-related complications and metabolic derangements. In practice, the "administration" of TPN encompasses not only the infusion itself but also the selection and placement of the most appropriate venous access device, verification of catheter tip location, determination of infusion schedules and rates, coordination with concomitant medications, and the implementation of monitoring systems that detect complications early and support timely adjustment of the prescription. TPN is administered through a central venous catheter, defined as an intravascular access device whose tip terminates in a large central vein—typically the superior vena cava (SVC) or at the cavoatrial junction near the right atrium. Central venous access is used to deliver not only parenteral nutrition but also medications, chemotherapy, vasoactive infusions, and other therapies that require rapid dilution in high-flow venous circulation. Establishing such access may be accomplished through a peripherally inserted central catheter (PICC), a centrally inserted central venous catheter, or an implanted port.[16] The clinical choice among these devices depends on anticipated duration of therapy, patient anatomy and comorbidities, expected outpatient versus inpatient use, infection risk profile, and the logistical requirements of ongoing care. While these devices share a common endpoint in central venous circulation, they differ in insertion technique, maintenance burden, and complication patterns, and these differences influence how TPN is delivered over short, intermediate, or prolonged courses.

A PICC line is often selected when TPN is anticipated for weeks to months, particularly in patients requiring stable, durable access that can be maintained outside intensive care settings.[17] PICC insertion typically occurs through peripheral upper extremity veins, commonly the basilic, cephalic, brachial, or median cubital vein. Among these, the basilic vein is often preferred because it tends to have a larger caliber and a relatively superficial anatomical course, facilitating cannulation and permitting placement of catheters that can accommodate higher flow rates and reduce thrombosis risk compared with smaller veins.[17] After insertion, the catheter advances centrally through the basilic vein into the axillary vein, then into the subclavian system, ultimately positioning the tip in the superior vena cava.[17] This pathway highlights a key advantage of PICCs: they offer central access without the need for direct puncture of major central veins in the neck or chest, thereby reducing the risk of certain mechanical complications such as pneumothorax. However, PICCs are not free of risk; they are associated with catheter-related thrombosis, occlusion, malposition, and infection, and therefore require careful site assessment, securement, and maintenance protocols. For TPN specifically, PICCs must be of adequate lumen size and appropriate material to support infusion of hyperosmolar solutions and to minimize catheter dysfunction during prolonged continuous infusion. Centrally inserted central venous catheters represent another major route for TPN administration and are commonly used when therapy is expected to extend for months to years or when immediate central access is needed in critically ill patients.[18] These catheters may be inserted into one of three large central veins: the internal jugular, subclavian, or femoral vein.[18] Internal jugular access is frequently favored in many acute care contexts because it provides a direct path to the SVC and allows real-time ultrasound guidance, which improves insertion safety and reduces inadvertent arterial puncture. Subclavian access can be advantageous for longer-term comfort and lower infection rates in some settings, yet it carries a higher risk of mechanical complications such as pneumothorax, particularly when ultrasound guidance is limited. Femoral access may be used when upper body sites are inaccessible or contraindicated, but femoral catheters are often associated with higher infection risk and limitations in mobility, making them less desirable for longer durations unless alternative sites cannot be used. For patients receiving prolonged TPN, the decision to use a centrally inserted catheter involves careful consideration of anticipated duration, patient mobility, infection risk, and whether the catheter will be used for multiple infusions beyond nutrition. Regardless of insertion site, verification of catheter tip placement is critical because malposition can lead to arrhythmias, inadequate dilution with higher risk of venous injury, or thrombosis. In clinical practice, imaging confirmation—such as radiography or other tip confirmation technology—is typically used to ensure appropriate location in the SVC or cavoatrial region.

For the longest durations of therapy—often years—an implanted port may be considered.[18] Implantable ports are surgically placed devices consisting of a reservoir implanted beneath the skin of the chest, connected to a catheter that terminates in the superior vena cava. Ports provide the advantage of being fully subcutaneous when not accessed, which can improve patient comfort, reduce the external catheter burden, and potentially lower infection risk associated with external lumens in some populations. These benefits are particularly

relevant for patients requiring long-term intermittent access and those who desire improved quality of life while receiving chronic infusion therapy. When a port is accessed, a special noncoring needle enters the reservoir through the skin, enabling infusion of TPN under sterile technique. Although ports can be durable, they still require careful maintenance, and accessing them repeatedly introduces procedural demands that must be supported by trained staff and strict aseptic technique. The preference for central venous access in TPN administration is primarily driven by the osmolarity of TPN solutions. Standard TPN formulations often exceed osmolarity thresholds that peripheral veins can tolerate, and infusion through a peripheral intravenous catheter can cause chemical phlebitis, vein irritation, pain, and loss of peripheral access. For this reason, TPN is not administered as peripheral parenteral nutrition (PPN) when osmolarity is high. PPN is typically limited to solutions with osmolarity below approximately 900 mOsm, which requires lower concentrations of dextrose and amino acids, thereby necessitating larger infusion volumes to achieve nutritional targets. Because delivering adequate calories through low-osmolarity solutions is challenging, PPN often relies on higher lipid contributions and may still be insufficient for patients with high caloric requirements or fluid restrictions. Consequently, for most adult patients requiring full nutritional replacement, central infusion is the standard approach, ensuring rapid dilution in high-flow venous circulation and enabling delivery of concentrated nutrients without local venous toxicity.

Administration also varies meaningfully across specific patient populations, where organ dysfunction and physiologic states alter nutritional requirements, metabolic tolerance, and complication risk. In patients with hepatic impairment, particularly those with cirrhosis, rapid initiation of parenteral nutrition is recommended when moderate to severe malnutrition is present and when oral or enteral nutrition cannot be delivered adequately. This recommendation reflects the high prevalence of protein-energy malnutrition in advanced liver disease and its association with worsened outcomes. Parenteral nutrition is also considered in patients with hepatic encephalopathy (HE) and unprotected airways, where the risk of aspiration makes enteral feeding hazardous.[19][20] However, nutritional management in liver disease is complicated by substantial inter-individual variability in energy expenditure and substrate utilization. For this reason, when available, resting energy expenditure (REE) should be calculated using indirect calorimetry to individualize calorie delivery and minimize the risk of underfeeding or overfeeding.[19][20] The relevance of indirect calorimetry in this context is mechanistic: liver disease may alter glycogen storage, fat metabolism, and protein handling, and inaccurate estimation of caloric needs can exacerbate hyperglycemia, fluid retention, or hepatic fat accumulation. In renal impairment, and particularly in end-stage renal disease (ESRD), the risk of nutritional disorders is elevated due to reduced appetite, inflammation, metabolic acidosis, dialysis-related nutrient losses, and restrictions that complicate dietary intake. In hospitalized patients with acute kidney injury (AKI) or chronic kidney disease (CKD) who require medical nutrition therapy, indirect calorimetry is recommended to estimate energy expenditure and guide nutritional delivery, thereby avoiding the harmful consequences of overfeeding and underfeeding. When oral nutritional supplementation (ONS) and enteral nutrition (EN) are contraindicated, parenteral nutrition should generally be initiated within three to seven days, reflecting the need to prevent progressive catabolism in patients whose renal disease is frequently accompanied by systemic illness.[21][22] Protein delivery in AKI is particularly nuanced because clinicians seek to promote positive nitrogen balance while avoiding excessive azotemia; thus protein targets should be adjusted according to catabolic rate, renal function, and dialysis-associated amino acid losses. Renal replacement therapy (RRT) introduces additional biochemical vulnerabilities, as prolonged RRT is commonly associated with electrolyte abnormalities such as hypophosphatemia, hypokalemia, and hypomagnesemia, necessitating frequent monitoring and individualized electrolyte supplementation in the TPN prescription.[21][22] Trace element status is also relevant, as requirements may increase in ESRD, critical illness, and in the setting of high effluent losses during RRT. Clinicians are advised to monitor and supplement trace elements with special attention to selenium, zinc, and copper, recognizing that deficiency can impair immune function, wound healing, and antioxidant defenses.[21][22] These renal-specific considerations demonstrate that "administration" is not simply infusing a standard bag; it is an ongoing clinical process of iterative adjustment based on laboratory data and evolving clinical status.

Special physiologic states such as lactation and pregnancy introduce additional considerations. In breastfeeding, available evidence from a literature review suggests that women receiving TPN have breastfed their infants, indicating that TPN does not inherently preclude lactation.[23] Moreover, the use of intravenous amino acids in postpartum mothers has been suggested to potentially hasten the onset of lactation and improve weight gain in breastfed infants, implying that adequate maternal protein substrate availability may support milk production and infant growth in situations where maternal nutrition would otherwise be compromised.[23] Clinically, this underscores the need for individualized counseling and monitoring, including consideration of maternal hydration, electrolyte balance, and overall caloric adequacy during TPN

therapy in lactating patients. Pregnancy presents a more complex clinical calculus because maternal malnutrition is clearly associated with adverse perinatal outcomes, yet the literature on pregnancy outcomes among women on TPN remains limited. The association between low pre-pregnancy body mass index and poor gestational weight gain with unfavorable perinatal outcomes is well established, which provides a physiologic rationale for aggressive nutritional support when indicated.[24] At the same time, parenteral nutrition in pregnancy carries risks, including potentially life-threatening complications such as sepsis and thromboembolism. Although advancements in TPN technology and catheter care have reduced maternal safety concerns, the American College of Obstetricians and Gynecologists (ACOG) emphasizes that enteral tube feeding should be used preferentially for nutritional support during pregnancy when feasible, given the reported serious complications associated with parenteral nutrition.[25] When parenteral nutrition is unavoidable, peripherally inserted central catheter lines may be used to avoid some complications associated with certain centrally inserted catheters, although PICCs still carry substantial morbidity and should be employed only when enteral feeding is not feasible.[25] These recommendations highlight that TPN administration in pregnancy requires stringent risk–benefit analysis, careful line selection, and close multidisciplinary follow-up involving obstetrics, nutrition support teams, and pharmacy.

The COVID-19 pandemic introduced unique administrative and operational challenges to parenteral nutrition delivery, particularly in critically ill, mechanically ventilated patients. Such patients often require prolonged intensive care unit stays and are susceptible to significant energy and protein deficits, especially when enteral nutrition is poorly tolerated or contraindicated due to hemodynamic instability, gastrointestinal dysmotility, or aspiration risk. In these circumstances, clinicians may need to transition to parenteral nutrition to meet nutritional targets. During the pandemic, a notable shift in prescribing patterns occurred, including movement away from soybean oil–based lipid injectable emulsions toward alternative lipid products perceived to have a lower inflammatory profile, reflecting heightened attention to immune modulation and inflammation in severe viral illness.[26] Operationally, the demand for multi-chamber-bag parenteral nutrition products increased, in part because these products reduce the time pharmacists and pharmacy technicians spend in sterile compounding areas, thereby decreasing the consumption of personal protective equipment and allowing redistribution of pharmacy workforce toward other urgent responsibilities.[26] Infection-control considerations were also prominent: nursing staff were advised to protect infusion tubing with a protective layer to reduce contamination risk, and consolidation of timing for medication administration and parenteral nutrition was recommended to minimize room entries and exposure events. Metabolically, patients with COVID-19 were recognized as being prone to hypertriglyceridemia, which has direct relevance for lipid administration in TPN; therefore, serum triglyceride concentrations were recommended at baseline and again within 24 to 48 hours after initiation of parenteral nutrition to guide safe lipid dosing and identify early intolerance.[26] These pandemic-era adaptations illustrate that TPN administration is sensitive not only to patient physiology but also to healthcare system constraints and infection-control priorities.

In summary, TPN administration is anchored in central venous delivery, reflecting the high osmolarity of full nutritional formulations and the need for safe dilution within central circulation.[16] Device selection—whether PICC, centrally inserted catheter, or implanted port—depends on anticipated duration and patient-specific factors, with PICCs often used for weeks to months, central catheters for months to years, and implanted ports for long-term therapy extending over years.[17][18] Peripheral administration is limited to lower-osmolarity regimens and is generally unsuitable for full TPN due to venous irritation and inadequate nutrient density. Administration must also be tailored to specific populations, including patients with hepatic and renal impairment where indirect calorimetry, individualized protein strategies, and vigilant electrolyte and trace element monitoring are emphasized.[19][20][21][22] Lactation and pregnancy require individualized counseling and risk–benefit assessment, with enteral nutrition preferred in pregnancy when possible and parenteral strategies reserved for situations where enteral feeding is not feasible.[23][24][25] Finally, pandemic conditions demonstrated that administrative strategies can shift in response to infection-control requirements and metabolic risks such as hypertriglyceridemia, reinforcing the dynamic, multidisciplinary nature of TPN delivery.[26]

Adverse Effects

Total parenteral nutrition (TPN) is a lifesaving intervention for patients who cannot meet nutritional needs through the gastrointestinal tract; however, it is also a high-complexity therapy with clinically important adverse effects. These adverse events typically cluster into three interrelated domains: complications related to venous access, infectious complications associated with central catheter use, and metabolic or hepatobiliary abnormalities caused by rapid shifts in substrate delivery and micronutrient balance. Understanding these risks is essential for safe prescribing, appropriate monitoring, and timely prevention strategies, particularly because many patients

receiving TPN are already physiologically vulnerable due to critical illness, malnutrition, organ dysfunction, or prolonged hospitalization. For this reason, parenteral nutrition is widely regarded as a high-risk therapy requiring multidisciplinary oversight, and it has been specifically identified as high risk by the Institute for Safe Medication Practices (ISMP) due to safety concerns and the complexity of administration.[30] Adverse effects related to venous access begin with the process of establishing central venous catheterization, which is generally required because the osmolarity of TPN exceeds the tolerance of peripheral veins. Central venous access is associated with procedural and postprocedural hazards that may occur during insertion or later during catheter dwell time. Pneumothorax represents a classic insertion-related complication, particularly when catheters are placed via subclavian or internal jugular approaches, because inadvertent pleural puncture may occur if needle trajectory is imperfect or if anatomical landmarks are distorted. Air embolism is another serious but preventable risk, reflecting the potential entry of air into the venous system during insertion, catheter manipulation, line disconnection, or improper priming of tubing. Even small volumes of air can be clinically consequential in susceptible patients, and large emboli can cause acute cardiorespiratory compromise. Bleeding may occur from vascular puncture, coagulopathy, thrombocytopenia, or accidental arterial injury, and it ranges from minor hematoma to major hemorrhage depending on the site and patient risk factors. Venous thrombosis is a particularly relevant complication in TPN recipients because central venous catheters can disrupt endothelial integrity, promote local stasis, and provide a surface for fibrin deposition, thereby increasing thrombogenic risk. Thrombosis may present as limb swelling, catheter dysfunction, pain, or may remain clinically occult until complications occur. Vascular injury, including damage to adjacent structures or inadvertent arterial cannulation, remains a recognized procedural risk, reinforcing the importance of ultrasound guidance, operator expertise, and postinsertion confirmation protocols.[27][2] Collectively, these access-related complications demonstrate that the adverse effects of TPN are not confined to nutrient metabolism; they begin with the infrastructural requirement of reliable central venous delivery.

Infectious complications constitute one of the most clinically significant adverse effect categories because TPN requires central lines and because nutrient-rich solutions can support microbial growth if contamination occurs. Central line–associated bloodstream infection (CLABSI) is the most serious infectious risk and can result in sepsis, end-organ dysfunction, prolonged hospitalization, and increased mortality.[28] CLABSI risk reflects multiple factors, including catheter type and dwell time, insertion technique, maintenance quality, frequency of line access, hub contamination, and patient-related immunologic vulnerability. In addition to bloodstream infections, local skin infection can develop at the insertion site or exit site, presenting with erythema, tenderness, discharge, or localized cellulitis. While local infection may appear minor, it can serve as a precursor to deeper tunnel infection or bloodstream dissemination if not recognized and treated promptly. Because CLABSI prevention is highly dependent on care processes, TPN therapy inherently demands strict aseptic technique, standardized line care bundles, careful dressing management, and minimization of unnecessary line manipulations. The nursing and pharmacy teams often play a central role in infection prevention by ensuring correct tubing changes, appropriate filter use when indicated, and adherence to institutional protocols for sterile compounding and administration. Metabolic adverse effects represent a third major domain and often reflect the abrupt transition from inadequate intake to high-density intravenous substrate delivery. Refeeding syndrome is among the most feared metabolic complications and occurs when nutritional support is introduced to severely malnourished patients, leading to rapid intracellular shifts of electrolytes and water driven by insulin-mediated uptake of glucose and phosphate-dependent cellular processes. Chronic alcoholic patients and individuals who have been nothing-by-mouth (NPO) for more than seven to ten days are at heightened risk, and the syndrome is characterized by hypophosphatemia, hypokalemia, hypomagnesemia, fluid retention, and potentially life-threatening arrhythmias or respiratory failure if not prevented and treated early. Hyperglycemia is another common complication because TPN delivers continuous dextrose, and many hospitalized patients have insulin resistance due to stress hormones, infection, corticosteroids, or pre-existing diabetes. Persistent hyperglycemia can increase infection risk, cause osmotic diuresis and dehydration, and worsen electrolyte disturbances, making glucose monitoring and insulin adjustment integral to safe therapy. Conversely, hypoglycemia can occur if TPN is abruptly discontinued, because endogenous insulin levels may remain relatively elevated compared with the sudden reduction in glucose infusion. This complication is clinically important because it can cause neuroglycopenic symptoms, seizures, or loss of consciousness, but it is generally correctable with concentrated dextrose administration, such as 50% dextrose, and preventable through tapering strategies or provision of an alternative dextrose infusion when TPN is interrupted.[2] Serum electrolyte abnormalities beyond refeeding syndrome can occur throughout therapy due to evolving renal function, ongoing GI or wound losses, changes in acid–base status, and the electrolyte content of the prescribed formulation. These abnormalities require frequent

laboratory monitoring and individualized adjustment of sodium, potassium, magnesium, calcium, and phosphate content to maintain physiologic stability.

Certain micronutrient-related complications also deserve emphasis. Wernicke's encephalopathy is a neurologic emergency associated with thiamine deficiency and is particularly relevant in malnourished individuals, chronic alcohol use disorders, and patients undergoing refeeding without adequate vitamin supplementation. Because glucose administration can increase thiamine demand in carbohydrate metabolism, initiating TPN without sufficient thiamine can precipitate or unmask Wernicke's encephalopathy, which can present with altered mental status, ophthalmoplegia, and ataxia. This risk underscores why vitamin supplementation and thiamine repletion are critical components of TPN initiation in at-risk populations.[29][2] In addition, hepatobiliary complications such as parenteral-associated cholestasis can develop, particularly with prolonged parenteral nutrition. Cholestasis may present with elevations in cholestatic liver enzymes and bilirubin and can reflect multifactorial mechanisms including lack of enteral stimulation, altered bile flow, inflammatory effects of lipid formulations, and excessive caloric delivery. Monitoring liver function tests and reducing unnecessary overfeeding are therefore common preventive strategies, though risk is often influenced by the underlying disease state and duration of therapy. In summary, the adverse effects of TPN extend across venous access risks, infectious complications such as CLABSI, and a spectrum of metabolic abnormalities including refeeding syndrome, dysglycemia, electrolyte disturbances, and micronutrient deficiency syndromes such as Wernicke's encephalopathy.[27][28][29][2] Hepatobiliary complications such as parenteral-associated cholestasis further highlight that long-term therapy can alter organ function in clinically meaningful ways. Because these adverse events can be severe and are often preventable through standardized protocols, close monitoring, and multidisciplinary coordination, it is appropriate that parenteral nutrition is categorized as a high-risk therapy by the ISMP, reinforcing the need for systematic safeguards throughout prescribing, compounding, administration, and follow-up.[30]

Contraindications

Total parenteral nutrition (TPN) is a highly specialized therapy intended to provide complete nutritional support when oral and enteral routes are not feasible, unsafe, or insufficient. Because it requires central venous access, compounding complex sterile formulations, and close metabolic monitoring, the decision to prescribe TPN must be guided by a clear therapeutic goal and a rigorous evaluation of risks and expected benefit. In this context, several contraindications have been described, reflecting situations in which TPN is unlikely to achieve meaningful clinical improvement, may expose the patient to disproportionate harm, or is unnecessary because the gastrointestinal tract can be used. According to Maudar (2017), TPN is generally contraindicated in infants who have less than 8 cm of small bowel.[5] This threshold is clinically significant because extremely limited intestinal length can indicate a profound and often refractory form of intestinal failure in which long-term outcomes may depend on complex surgical reconstruction, intestinal rehabilitation, or transplantation, and where short-term TPN may not provide a realistic pathway toward nutritional autonomy. In such infants, the risks of catheter-related infection, liver injury, and metabolic complications are especially high, and nutritional strategies must be individualized within specialized pediatric programs rather than defaulting to conventional TPN pathways. Maudar (2017) also describes TPN as contraindicated in irreversibly decerebrate patients.[5] This contraindication is grounded in ethical and clinical reasoning: when neurological injury is irreversible and incompatible with recovery, artificial nutrition may not serve a rehabilitative or restorative purpose. In such cases, TPN can function as a life-prolonging intervention without meaningful improvement in quality of life or clinical trajectory, and it may prolong the dying process rather than supporting recovery. Similarly, TPN is contraindicated in patients with critical cardiovascular instability or major metabolic instabilities until these conditions are corrected.[5] The rationale is physiologic: rapid infusion of concentrated dextrose, lipids, and electrolytes can exacerbate hemodynamic fragility and worsen acid–base and electrolyte abnormalities, thereby increasing the risk of arrhythmias, pulmonary edema, and end-organ dysfunction. In patients requiring escalating vasopressors, experiencing uncontrolled shock, or demonstrating unstable glycemic and electrolyte profiles, the priority is stabilization. Only after hemodynamics and metabolic parameters are sufficiently controlled can intravenous nutrition be introduced in a manner that is safe and likely to be tolerated.

A major contraindication is simply the ability to feed via the gastrointestinal tract. When gastrointestinal feeding is possible, enteral nutrition is preferred, and TPN should not be used as a substitute for a functional and safe enteral route.[5] This principle reflects both efficacy and safety considerations: enteral feeding supports gut integrity and is associated with fewer central-line complications. Additionally, if the patient's nutritional status is good and only short-term nutritional support is required, TPN may be inappropriate because the risks and logistical burdens of central access and intensive monitoring may

outweigh any marginal benefit.[5] In these scenarios, supportive measures such as oral nutritional supplementation, temporary enteral feeding, or careful observation may be safer and more aligned with patient-centered goals. Finally, Maudar (2017) emphasizes that the lack of a therapeutic goal constitutes a contraindication, noting that TPN should not be used to prolong life when death is unavoidable.[5] This statement underscores an essential ethical dimension: TPN is a treatment, not merely a default supportive measure. Its use should be tied to a clear intention—such as bridging to recovery, supporting healing, or preventing deterioration during a reversible period of gastrointestinal failure—rather than serving as an intervention in the absence of achievable clinical endpoints. Contraindications also intersect with safety alerts specific to vulnerable populations. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for some intravenous fat emulsions due to an increased risk of death in preterm neonates associated with intravascular fat accumulation in the lungs.[31] This warning highlights that neonatal physiology differs substantially from adult physiology, particularly with respect to lipid clearance, pulmonary microcirculation vulnerability, and the risk of fat overload syndrome. Accordingly, clinicians must exercise heightened caution when selecting TPN therapy for preterm infants and must adhere to evidence-based guidelines that account for gestational age, lipid tolerance, infusion rates, and monitoring parameters.[31] The contraindication framework for TPN is therefore not static; it is continuously shaped by evolving safety evidence, device warnings, and population-specific vulnerabilities, reinforcing the need for specialized expertise in neonatal and pediatric nutrition support. Although not a contraindication per se, the administration pathway for TPN also involves safety measures designed to mitigate infection risk. The American Society for Parenteral and Enteral Nutrition (ASPEN) evidence-based guidelines suggest the use of a 1.2-micron in-line filter.[32] While these filters are not intended to function as standard infection-control devices, they have been described as efficacious in preventing Candida albicans infection in patients receiving parenteral nutrition.[32] This recommendation illustrates a broader concept: even when TPN is indicated, its use should be paired with layered safeguards that reduce preventable complications, especially in patients at heightened risk for fungal bloodstream infections.

Monitoring

Monitoring is central to safe and effective TPN therapy because parenteral nutrition is metabolically active, dynamically interacts with organ function, and can precipitate rapid biochemical changes—particularly during initiation and dose escalation. Contemporary practice therefore emphasizes structured identification of patients who are most likely to benefit from parenteral nutrition and rigorous surveillance during therapy to detect complications early and guide individualized adjustments. The American College of Gastroenterology recommends that the identification of critically ill patients who may benefit from parenteral nutrition should be made using validated scoring systems such as Nutrition Risk Screening 2002 (NRS-2002) or the Nutrition Risk in Critically Ill (NUTRIC) score.[20] These tools formalize assessment of nutritional risk and illness severity, helping clinicians determine which patients are most vulnerable to malnutrition-related harm and therefore most likely to derive net benefit from early nutritional intervention. This approach is clinically meaningful because indiscriminate use of TPN can expose low-risk patients to catheter-related and metabolic complications without producing substantial outcome improvement. Once TPN is initiated, monitoring must address both immediate infusion-related physiology and longer-term complications associated with sustained intravenous nutrient delivery. Maudar (2017) outlines several practical monitoring variables, including intake and output charting at 12-hour intervals, urine sugar monitoring every eight hours, daily serum electrolytes (sodium, potassium, bicarbonate, calcium, and chloride), daily serum creatinine and blood urea measurements, serum protein levels twice daily, and liver function tests twice weekly.[5] These measures reflect core safety domains. Intake and output monitoring helps detect fluid overload, dehydration, or evolving renal dysfunction—issues that are especially important because TPN contributes both fluid and osmotic load. Urine glucose monitoring, while less commonly emphasized in some modern protocols compared with point-of-care blood glucose monitoring, reflects the need to detect glycosuria as a signal of hyperglycemia and inadequate glucose handling. Daily electrolytes and renal function tests are essential because TPN can rapidly shift serum potassium, phosphate, magnesium, and sodium, particularly in refeeding states or in patients with fluctuating renal function, while blood urea and creatinine trends provide a window into nitrogen tolerance, hydration, and renal clearance capacity.

ASPEN guidelines also provide a stratified monitoring framework based on patient stability and the likelihood of metabolic disturbance.[33] Patients who have recently started TPN should be monitored daily until stable, with even more frequent monitoring if metabolic abnormalities are detected or if the patient is at risk for refeeding syndrome.[33] Refeeding syndrome is a well-recognized complication that can occur when nutrition is reintroduced in severely malnourished individuals, leading to severe electrolyte instability—most notably hypophosphatemia—and potentially serious outcomes such as respiratory distress, rhabdomyolysis, and acute kidney injury.[34]

Prevention is considered critical and is achievable through strategies such as initiating TPN at a slower rate than the calculated goal and gradually advancing as laboratory parameters stabilize.[34] In unstable and critically ill patients, daily monitoring continues until clinical and metabolic stability is achieved.[33] For stable hospitalized patients with no formulation changes for one week, monitoring may be spaced to every two to seven days, reflecting lower volatility and reduced risk of abrupt shifts.[33] For stable patients in hospital, home, or long-term care settings with no formulation changes for one week, monitoring may be performed every one to four weeks when clinically stable.[33] This tiered model supports efficient allocation of laboratory resources while preserving safety by recognizing that monitoring intensity should mirror clinical risk rather than follow a uniform schedule for all patients.

Toxicity

The toxicity profile of TPN is best understood as the cumulative toxicity potential of its individual components when delivered in excessive quantities, inappropriate ratios, or in physiologic states that reduce metabolic tolerance. A major toxicity pathway relates to excessive caloric delivery—particularly from dextrose and lipids—which can contribute to hepatic injury. Overfeeding increases the risk of hepatic steatosis, cholestasis, and inflammatory liver dysfunction, and it can also increase carbon dioxide production, complicating ventilator management in critically ill patients. The risk of hepatic toxicity can be reduced by moderating glucose delivery and balancing caloric provision with an appropriate lipid fraction, thereby decreasing the hepatic conversion of excess glucose into fat.[35] Mechanistically, when glucose infusion rates exceed metabolic capacity, hyperinsulinemia promotes hepatic lipogenesis and triglyceride accumulation, contributing to fatty liver changes. A glucose infusion rate greater than 5 mg/kg/min has been associated with fatty liver development because excess circulating glucose drives lipogenesis and insulin secretion, amplifying hepatic fat deposition.[35] Preventive strategies described include limiting dextrose to under 5 g/kg/day and maintaining a glucose infusion rate below 5 mg/kg/min, using cyclic parenteral nutrition—such as an eight-hour cycle—to reduce continuous insulin stimulation, and substituting approximately 30% of dextrose-derived energy with lipids to reduce carbohydrate load while maintaining caloric adequacy.[35] These measures underscore that toxicity is often preventable when dosing adheres to physiological constraints and when prescriptions are adjusted in response to laboratory signals and clinical status.

In pediatric critical care, toxicity considerations extend beyond classical metabolic complications and into the realm of cellular adaptive processes. Evidence suggests that parenteral nutrition supplementation, as opposed to withholding PN in the earliest phase of critical illness, may be harmful in pediatric intensive care unit (PICU) populations. Specifically, clinicians are advised to withhold parenteral nutrition supplementation during the first week in the PICU regardless of age or nutritional status, with the reasoning that amino acids supplied in PN may suppress autophagy, a cellular process necessary for removal of damaged cellular components during stress.[36] When autophagy is suppressed, cellular repair mechanisms may be impaired, and excess amino acids may be diverted toward urea production. Elevated urea levels can impose additional burden on the kidneys and liver, potentially worsening organ stress in critically ill children.[36] This perspective reframes TPN toxicity as not only a matter of overfeeding or electrolyte imbalance but also as a potential disruption of adaptive biology during early critical illness. Long-term use of TPN, spanning weeks to months, can also produce rare trace element toxicities, with manganese toxicity being a notable example. Because TPN bypasses gastrointestinal regulatory mechanisms that normally limit absorption, manganese exposure via TPN has high bioavailability. Over time, manganese can accumulate and deposit in the liver, brain, and bone, with the brain being particularly susceptible due to deposition in the globus pallidus and striatum within the basal ganglia.[37] Manganese preferentially affects dopaminergic neurons in these regions, producing extrapyramidal symptoms that can resemble Parkinson's disease. Importantly, idiopathic Parkinson's disease can be differentiated by its characteristic neuronal involvement, particularly within the substantia nigra, whereas manganese toxicity has a different distribution pattern within the basal ganglia.[37] This toxicity emphasizes why trace element dosing should not be treated as a fixed "add-on," but should be monitored and adjusted during long-term therapy, especially when hepatic clearance is impaired or when TPN duration is extended. An additional toxicity pathway involves oxidative damage due to peroxide and reactive oxygen species (ROS) formation within parenteral nutrition solutions exposed to light. Peroxide formation can occur when PN is exposed to light and phototherapy, and premature infants are particularly susceptible to downstream consequences such as bronchopulmonary dysplasia, necrotizing enterocolitis, and retinopathy of prematurity.[38] To mitigate this risk, ASPEN guidelines recommend photoprotection of PN products beginning during the compounding process and continuing until the entire PN infusion is administered.[38] This recommendation highlights that toxicity is not only patient-dependent but also process-dependent: the way PN is prepared, stored, and administered can influence oxidative load and clinical outcomes, particularly in neonatal populations.

Enhancing Healthcare Team Outcomes

Safe and effective TPN therapy is inherently interprofessional because it involves clinical decision-making, nutrition assessment, sterile compounding, catheter care, laboratory interpretation, and patient education across inpatient and outpatient settings. TPN administration requires a coordinated healthcare team that includes, at minimum, the clinician, pharmacist, dietician, and nutrition nurse specialist, with extended contributors often including social workers, occupational therapists, and wound management nurses.[39] The clinician is responsible for determining the indication for parenteral nutrition, clarifying therapeutic goals, and selecting the appropriate form of nutritional support based on the patient's medical condition and gastrointestinal function. This clinician also coordinates TPN within the broader care plan, integrating input from the primary medical team and specialists to ensure that nutrition therapy supports overall clinical objectives rather than operating in isolation. Pharmacists provide the sterile preparation of parenteral nutrition and serve a critical safety role by evaluating formulation stability, ensuring appropriate concentrations, and identifying potential drug–nutrient interactions or compatibility concerns.[39] Because PN compounding involves complex physicochemical relationships—such as calcium–phosphate solubility, lipid emulsion stability, and trace element interactions—the pharmacist's oversight is central to preventing precipitation, emulsion cracking, and contamination. Dieticians assess nutritional status, estimate energy and protein requirements, and design the feeding regimen, translating clinical objectives into nutrient targets that can be operationalized through PN prescriptions.[39] The nutrition nurse specialist supervises catheter and tube care, monitors infusion practices, supports infection prevention protocols, and serves as a patient advocate, particularly when patients transition to home PN. This specialist often trains patients and caregivers to manage central lines, recognize signs of infection or catheter dysfunction, and adhere to aseptic technique at home, which is essential for reducing CLABSI and maintaining long-term access. Effective team outcomes depend on open communication and accurate, timely documentation, ensuring that changes in laboratory values, patient status, line condition, or infusion tolerance are visible to all team members who participate in care decisions.[39] This shared situational awareness is especially important because PN prescriptions often require frequent adjustment in response to evolving renal function, glycemic control, electrolyte shifts, and fluid balance. ASPEN guidelines further recommend comprehensive education and demonstrated competency among clinicians, pharmacists, dieticians, and pharmacy technicians involved in parenteral nutrition services.[40] Evidence suggests that interprofessional education programs and collaborative practice models can significantly optimize parenteral nutrition–related safety and outcomes, reinforcing that the reliability of PN therapy is closely tied to system-level training, standardized processes, and coordinated teamwork rather than to isolated individual expertise.[40]

Conclusion:

Total parenteral nutrition represents a cornerstone therapy for patients with nonfunctional or inaccessible gastrointestinal tracts, yet its complexity demands a systematic, multidisciplinary approach. While TPN can prevent severe malnutrition and support recovery in critical illness, it is not without substantial risks. Catheter-related infections, metabolic derangements, and hepatobiliary complications underscore the need for rigorous protocols and continuous monitoring. Ethical considerations, such as avoiding TPN in irreversible conditions or when enteral feeding is feasible, remain central to appropriate use. Pharmacists are integral to ensuring formulation stability, preventing incompatibilities, and guiding safe administration practices, while dieticians and clinicians tailor nutrient delivery to dynamic patient needs. Emerging evidence on glutamine supplementation, photoprotection, and autophagy suppression in pediatric critical care further illustrates the evolving nature of TPN management. Ultimately, success hinges on individualized therapy, adherence to evidence-based guidelines, and proactive risk mitigation strategies. By fostering interprofessional collaboration and prioritizing patient safety, healthcare teams can maximize the therapeutic benefits of TPN while minimizing its inherent hazards.

References:

1. Braunschweig C, Liang H, Sheean P. Indications for administration of parenteral nutrition in adults. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. 2004 Jun:19(3):255-62
2. Chowdary KV, Reddy PN. Parenteral nutrition: Revisited. Indian journal of anaesthesia. 2010 Mar:54(2):95-103. doi: 10.4103/0019-5049.63637.
3. Weimann A, Ebener Ch, Holland-Cunz S, Jauch KW, Hausser L, Kemen M, Kraehenbuehl L, Kuse ER, Laengle F, Working group for developing the guidelines for parenteral nutrition of The German Association for Nutritional Medicine. Surgery and transplantation - Guidelines on Parenteral Nutrition, Chapter 18. German medical science : GMS e-journal. 2009 Nov 18:7():Doc10. doi: 10.3205/000069.
4. Messing B. [Parenteral nutrition: indications and techniques]. Annales de medecine interne. 2000 Dec:151(8):652-8
5. Maudar KK. TOTAL PARENTERAL NUTRITION. Medical journal, Armed Forces

India. 1995 Apr:51(2):122-126. doi: 10.1016/S0377-1237(17)30942-5.
6. Gotthardt DN, Gauss A, Zech U, Mehrabi A, Weiss KH, Sauer P, Stremmel W, Büchler MW, Schemmer P. Indications for intestinal transplantation: recognizing the scope and limits of total parenteral nutrition. Clinical transplantation. 2013 Jul-Aug:27 Suppl 25():49-55. doi: 10.1111/ctr.12161.
7. Tabor E. Tutorial on How the US Food and Drug Administration Regulates Parenteral Nutrition Products. JPEN. Journal of parenteral and enteral nutrition. 2020 Feb:44(2):174-181. doi: 10.1002/jpen.1752.
8. Slattery E, Rumore MM, Douglas JS, Seres DS. 3-in-1 vs 2-in-1 parenteral nutrition in adults: a review. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. 2014 Oct:29(5):631
9. Mohandas KM, Shastri YM, Shirodkar M. Total parenteral nutrition. The National medical journal of India. 2003 Jan-Feb:16(1):29-33
10. Wischmeyer PE. The glutamine debate in surgery and critical care. Current opinion in critical care. 2019 Aug:25(4):322-328. doi: 10.1097/MCC.0000000000000633.
11. Tsujimoto T, Shimizu K, Hata N, Takagi T, Uejima E, Ogura H, Wasa M, Shimazu T. Both high and low plasma glutamine levels predict mortality in critically ill patients. Surgery today. 2017 Nov:47(11):1331-1338. doi: 10.1007/s00595-017-1511-0.
12. Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, Elke G, Berger MM, Day AG, Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. The New England journal of medicine. 2013 Apr 18:368(16):1489-97. doi: 10.1056/NEJMoa1212722.
13. Stawny M, Olijarczyk R, Jaroszkiewicz E, Jelińska A. Pharmaceutical point of view on parenteral nutrition. TheScientificWorldJournal. 2013:2013():415310. doi: 10.1155/2013/415310.
14. Fox LM, Wilder AG, Foushee JA. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013 Mar 15:70(6):520-4. doi: 10.2146/ajhp110715.
15. Newton DW. Y-site Compatibility of Intravenous Drugs With Parenteral Nutrition. JPEN. Journal of parenteral and enteral nutrition. 2013 May-Jun:37(3):297-9. doi: 10.1177/0148607112465653.
16. Kovacevich DS, Corrigan M, Ross VM, McKeever L, Hall AM, Braunschweig C. American Society for Parenteral and Enteral Nutrition Guidelines for the Selection and Care of Central Venous Access Devices for Adult Home Parenteral Nutrition Administration. JPEN. Journal of parenteral and enteral nutrition. 2019 Jan:43(1):15-31. doi: 10.1002/jpen.1455.
17. Gonzalez R, Cassaro S. Percutaneous Central Catheter. StatPearls. 2025 Jan
18. Leib AD, England BS, Kiel J. Central Line(Archived). StatPearls. 2025 Jan
19. Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clinical nutrition (Edinburgh, Scotland). 2019 Apr:38(2):485-521. doi: 10.1016/j.clnu.2018.12.022.
20. McClave SA, DiBaise JK, Mullin GE, Martindale RG. ACG Clinical Guideline: Nutrition Therapy in the Adult Hospitalized Patient. The American journal of gastroenterology. 2016 Mar:111(3):315-34; quiz 335. doi: 10.1038/ajg.2016.28.
21. Fiaccadori E, Sabatino A, Barazzoni R, Carrero JJ, Cupisti A, De Waele E, Jonckheer J, Singer P, Cuerda C. ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clinical nutrition (Edinburgh, Scotland). 2021 Apr:40(4):1644-1668. doi: 10.1016/j.clnu.2021.01.028.
22. Brown RO, Compher C, American Society for Parenteral and Enteral Nutrition Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support in adult acute and chronic renal failure. JPEN. Journal of parenteral and enteral nutrition. 2010 Jul-Aug:34(4):366-77. doi: 10.1177/0148607110374577.
23. . Parenteral Nutrition. Drugs and Lactation Database (LactMed®). 2006
24. Borbolla Foster A, Dixon S, Tyrrell-Price J, Trinder J. Pregnancy and lactation during long-term total parenteral nutrition: A case report and literature review. Obstetric medicine. 2016 Dec:9(4):181-184
25. Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy. Obstetrics and gynecology. 2018 Jan:131(1):e15-e30. doi: 10.1097/AOG.0000000000002456.
26. Wells Mulherin D, Walker R, Holcombe B, Guenter P. ASPEN Report on Nutrition Support Practice Processes With COVID-19: The First Response. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. 2020 Oct:35(5):783-791. doi: 10.1002/ncp.10553.
27. Parienti JJ, Mongardon N, Mégarbane B, Mira JP, Kalfon P, Gros A, Marqué S, Thuong M, Pottier V, Ramakers M, Savary B, Seguin A, Valette X, Terzi N, Sauneuf B, Cattoir V, Mermel

LA, du Cheyron D, 3SITES Study Group. Intravascular Complications of Central Venous Catheterization by Insertion Site. The New England journal of medicine. 2015 Sep 24:373(13):1220-9. doi: 10.1056/NEJMoa1500964.
28. Latif A, Halim MS, Pronovost PJ. Eliminating Infections in the ICU: CLABSI. Current infectious disease reports. 2015 Jul:17(7):491. doi: 10.1007/s11908-015-0491-8.
29. Mattioli S, Miglioli M, Montagna P, Lerro MF, Pilotti V, Gozzetti G. Wernicke's encephalopathy during total parenteral nutrition: observation in one case. JPEN. Journal of parenteral and enteral nutrition. 1988 Nov-Dec:12(6):626-7
30. Sanchez Acera E, Arenas Villafranca JJ, Abilés J, Faus Felipe V. [Hypersensibility reaction to parenteral nutrition approach; a case report]. Nutricion hospitalaria. 2014 Mar 1:29(3):695-7. doi: 10.3305/nh.2014.29.3.7156.
31. Boullata JI, Gilbert K, Sacks G, Labossiere RJ, Crill C, Goday P, Kumpf VJ, Mattox TW, Plogsted S, Holcombe B, American Society for Parenteral and Enteral Nutrition. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN. Journal of parenteral and enteral nutrition. 2014 Mar-Apr:38(3):334-77. doi: 10.1177/0148607114521833.
32. Worthington P, Gura KM, Kraft MD, Nishikawa R, Guenter P, Sacks GS, ASPEN PN Safety Committee. Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. 2021 Feb:36(1):29-39. doi: 10.1002/ncp.10587.
33. Ayers P, Adams S, Boullata J, Gervasio J, Holcombe B, Kraft MD, Marshall N, Neal A, Sacks G, Seres DS, Worthington P, American Society for Parenteral and Enteral Nutrition. A.S.P.E.N. parenteral nutrition safety consensus recommendations. JPEN. Journal of parenteral and enteral nutrition. 2014 Mar-Apr:38(3):296-333. doi: 10.1177/0148607113511992.
34. Lakananurak N, Gramlich L. The Role of Preoperative Parenteral Nutrition. Nutrients. 2020 May 6:12(5):. doi: 10.3390/nu12051320.
35. Guglielmi FW, Boggio-Bertinet D, Federico A, Forte GB, Guglielmi A, Loguercio C, Mazzuoli S, Merli M, Palmo A, Panella C, Pironi L, Francavilla A. Total parenteral nutrition-related gastroenterological complications. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2006 Sep:38(9):623-42
36. Jacobs A, Verlinden I, Vanhorebeek I, Van den Berghe G. Early Supplemental Parenteral Nutrition in Critically Ill Children: An Update. Journal of clinical medicine. 2019 Jun 11:8(6):. doi: 10.3390/jcm8060830.
37. Khan A, Hingre J, Dhamoon AS. Manganese Neurotoxicity as a Complication of Chronic Total Parenteral Nutrition. Case reports in neurological medicine. 2020:2020():9484028. doi: 10.1155/2020/9484028.
38. Robinson DT, Ayers P, Fleming B, Gura KM, Gutsul L, Michalski A, Holcombe B, Sacks GS. Recommendations for photoprotection of parenteral nutrition for premature infants: An ASPEN position paper. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. 2021 Oct:36(5):927-941. doi: 10.1002/ncp.10747.
39. Nightingale J. Nutrition support teams: how they work, are set up and maintained. Frontline gastroenterology. 2010 Oct:1(3):171-177. doi: 10.1136/fg.2009.000224.
40. Solomon DM, Emery EZ, Kavelak HL, Pontiggia L, Hollands JM, Bingham AL. Impact of Implementation of the American Society for Parenteral and Enteral Nutrition Model for Parenteral Nutrition Order Writing and Review on Competency, Attitudes, and Perceptions. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. 2019 Aug:34(4):597-605. doi: 10.1002/ncp.10237.
.